Structure (Image 1)
Desvenlafaxine
Product Images NDC 53002-1801
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 53002-1801). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
1 (Image 2)
1 (Image 3)
This text appears to display data related to the impact of CYP3A4 inhibitors on the maximum concentration (Cmax) of Ketoconazole. It includes geometric mean ratios for the change relative to a reference, with corresponding confidence intervals.*
3 (Image 4)
Figure 4 (Image 5)
This text appears to be a graph showing the estimated proportion of patients experiencing a relapse over time (in days from randomization) for Desvenlafaxine Extended-Release Tablets 50 mg and Placebo. The y-axis appears to show the percentage of patients experiencing a relapse, with values ranging from 0% to 50% and the x-axis appears to be the number of days from randomization, ranging from 0 to 200.*
Figure 5 (Image 6)
The text represents a graph displaying the estimated proportion of patients with relapse over time (in days from randomization) for a medication called Desvenlafaxine Extended-Release Tablets compared to a placebo. The graph shows that at day 50, the estimated proportion of patients with relapse was around 8% for both the medication and placebo, but the medication showed a lower estimated proportion of patients with relapse (around 3%) at day 150.*
Label Image (Lbl530021801)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
